ArticleJournal of inflammation research2026
High-Sensitivity Troponin I and NT-proBNP as Early Indicators of Disease Severity and Prognostic Markers in Immune Checkpoint Inhibitor-Associated Fulminant Myocarditis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The study aims to investigate the utility of high-sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) measured at initial presentation as indicators of disease severity and prognostic markers in patients with immune checkpoint inhibitor (ICI)-associated myocarditis. While these biomarkers reflect myocardial injury and ventricular dysfunction-consequences of the underlying pathology-their levels at diagnosis may aid in early risk stratification and identification of patients likely to follow a fulminant course. Methods: This study implemented a retrospective cohort design, involving 341 patients identified with myocarditis associated with immune checkpoint inhibitors (ICIs). The participants were divided into two categories: those with fulminant myocarditis (62 subjects) and those with non-fulminant myocarditis (279 subjects). An in-depth examination was conducted on their clinical features, biomarker concentrations, and health outcomes. To ascertain the predictive capability of these biomarkers, multivariable logistic regression analyses and survival assessments were utilized. Additionally, a subgroup analysis was carried out by classifying patients into high and low biomarker groups according to the optimal cutoff points determined through receiver operating characteristic (ROC) curve evaluations. The subgroups were then compared regarding treatment modalities (including immunosuppressive therapy and mechanical circulatory support) and clinical outcomes (including ICU admission, complications, and survival). Results: Patients with fulminant myocarditis had significantly higher hs-cTnI (1.38 ± 0.56 vs. 0.22 ± 0.10ng/mL) and NT-proBNP (2384.43 ± 912.67 vs. 528.72 ± 192.33pg/mL) levels (both Conclusion: Hs-cTnI and NT-proBNP levels at presentation are strong indicators of myocardial injury severity and ventricular dysfunction in ICI-associated myocarditis. Their measurement facilitates early risk stratification, identifying patients at highest risk for fulminant disease who may benefit from intensive monitoring and timely intervention. Additionally, pre-existing cardiovascular comorbidities remain crucial for identifying vulnerable populations prior to ICI initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.